公开(公告)号：EP2082745A1

公开(公告)日：2009-07-29

申请号：EP07025216.8

申请日：2007-12-28

申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts ,  Ruprecht-Karls-Universität Heidelberg

发明人： Rommelaere, Jean ,  Raykov, Zahari ,  Schlehofer, Jörg ,  Kiprijanova, Irina ,  Heimberger, Tanja ,  Angelova, Assia ,  Geletneky, Karsten ,  Aprahamian, Marc

IPC分类号： A61K35/76 ,  A61K31/4188 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/495 ,  A61K31/4188 ,  A61K31/7068 ,  A61K35/768 ,  C12N2750/14032 ,  A61K2300/00

摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

摘要翻译： 描述了含有（a）细小病毒和（b）化学治疗剂的药物组合物，优选作为分开的实体。 细小病毒可能基于细小病毒H1，LuIII，小鼠微小病毒（MMV），小鼠细小病毒（MPV），大鼠微小病毒（RMV），大鼠细小病毒（RPV），大鼠病毒（RV），基于上述病毒物种的载体 ，和/或能够积极产生上述病毒物种的细胞。 该药物组合物有利于治疗肿瘤。 细小病毒或本发明的辅助物具有特殊用途的肿瘤包括神经胶质瘤，成神经管细胞瘤，脑膜瘤和胰腺癌。 优选的化学治疗剂是吉西他滨和替莫唑胺。

公开(公告)号：EP2266587A1

公开(公告)日：2010-12-29

申请号：EP09007432.9

申请日：2009-06-04

申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts ,  Ruprecht-Karls-Universität Heidelberg

发明人： Rommelaere, Jean ,  Geletneky, Karsten ,  Koch, Ute ,  Raykov, Zahari ,  Grekova, Svitlana ,  Kiprijanova, Irina ,  Aprahamian, Marc

IPC分类号： A61K35/76

CPC分类号： A61K35/768 ,  C12N2750/14332

摘要： Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor.

摘要翻译： 描述了用于预防肿瘤复发的细小病毒，优选恶性脑肿瘤或胰腺肿瘤。

公开(公告)号：EP2075003B1

公开(公告)日：2010-09-01

申请号：EP07025215.0

申请日：2007-12-28

申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts ,  Ruprecht-Karls-Universität Heidelberg

发明人： Raykov, Zahari ,  Rommelaere, Jean ,  Giese, Nathalia ,  Aprahamian, Marc

IPC分类号： A61K35/76 ,  C12N7/00

CPC分类号： A61K35/768 ,  A61K2039/55561 ,  C12N7/00 ,  C12N2750/14321 ,  C12N2750/14332

摘要： A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.

公开(公告)号：EP2383577A1

公开(公告)日：2011-11-02

申请号：EP10004592.1

申请日：2010-04-30

申请人： Deutsches Krebsforschungszentrum ,  Ruprecht-Karls-Universität Heidelberg ,  Universitätsklinikum Heidelberg

发明人： Giese, Nathalia ,  Werner, Jens ,  Büchler, Markus ,  Giese, Thomas ,  Däffler, Laurent ,  Cziepluch, Celina ,  Rommelaere, Jan ,  Raykov, Zahari

IPC分类号： G01N33/574 ,  A61K35/76

CPC分类号： G01N33/68 ,  G01N33/57484

摘要： Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.

摘要翻译： 描述了一种用于预测患者的响应于chemovirotherapy或radiovirotherapy，包括：从患者暴露原发性肿瘤细胞，一种诊断方法例如脑瘤或胰腺癌，与（i）细小病毒和/或获得的肿瘤细胞（ⅱ ）化学治疗剂或放射疗法，和确定性采矿ISG15的表达或浓度的降低。

公开(公告)号：EP2075003A1

公开(公告)日：2009-07-01

申请号：EP07025215.0

申请日：2007-12-28

申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts ,  Ruprecht-Karls-Universität Heidelberg

发明人： Raykov, Zahari ,  Rommelaere, Jean ,  Giese, Nathalia ,  Aprahamian, Marc

IPC分类号： A61K35/76 ,  C12N7/00

CPC分类号： A61K35/768 ,  A61K2039/55561 ,  C12N7/00 ,  C12N2750/14321 ,  C12N2750/14332

摘要： A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.

摘要翻译： 特征在于富含CpG的基因组的细小病毒，其中所述基因组含有至少2个额外的CpG插入物，其不存在于野生型基因组中，以及使用所述细小病毒，例如基于细小病毒H1，LuIII的细小病毒 ，小鼠微病毒（MMV），小鼠细小病毒（MPV），大鼠微小病毒（RMV），大鼠细小病毒（RPV），大鼠病毒（RV），基于上述病毒物种的载体和/或能够主动产生 前述用于制备药物组合物的病毒物质，例如用于治疗癌症，优选胰腺癌，肝癌或淋巴瘤。

公开(公告)号：EP2431045B1

公开(公告)日：2013-03-06

申请号：EP11003657.1

申请日：2008-12-23

申请人： Deutsches Krebsforschungszentrum ,  Ruprecht-Karls-Universität Heidelberg

发明人： Rommelaere, Jean ,  Raykov, Zahari ,  Schlehofer, Jörg ,  Kiprijanova, Irina ,  Heimberger, Tanja ,  Angelova, Assia ,  Geletneky, Karsten ,  Aprahamian, Marc

IPC分类号： A61K35/76 ,  A61K31/4188 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/495 ,  A61K31/4188 ,  A61K31/7068 ,  A61K35/768 ,  C12N2750/14032 ,  A61K2300/00

摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

公开(公告)号：EP2082745B1

公开(公告)日：2012-12-19

申请号：EP07025216.8

申请日：2007-12-28

申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts ,  Ruprecht-Karls-Universität Heidelberg

发明人： Rommelaere, Jean ,  Raykov, Zahari ,  Schlehofer, Jörg ,  Kiprijanova, Irina ,  Heimberger, Tanja ,  Angelova, Assia ,  Geletneky, Karsten ,  Aprahamian, Marc

IPC分类号： A61K35/76 ,  A61K31/4188 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/495 ,  A61K31/4188 ,  A61K31/7068 ,  A61K35/768 ,  C12N2750/14032 ,  A61K2300/00

摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

公开(公告)号：EP2431045A1

公开(公告)日：2012-03-21

申请号：EP11003657.1

申请日：2008-12-23

申请人： Deutsches Krebsforschungszentrum ,  Ruprecht-Karls-Universität Heidelberg

发明人： Rommelaere, Jean ,  Raykov, Zahari ,  Schlehofer, Jörg ,  Kiprijanova, Irina ,  Heimberger, Tanja ,  Angelova, Assia ,  Geletneky, Karsten ,  Aprahamian, Marc

IPC分类号： A61K35/76 ,  A61K31/4188 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/495 ,  A61K31/4188 ,  A61K31/7068 ,  A61K35/768 ,  C12N2750/14032 ,  A61K2300/00

摘要： Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of pancreatic cancer.

摘要翻译： 描述了含有（a）细小病毒和（b）化学治疗剂的药物组合物，优选作为分开的实体。 细小病毒可能基于细小病毒H1，LuIII，小鼠微小病毒（MMV），小鼠细小病毒（MPV），大鼠微小病毒（RMV），大鼠细小病毒（RPV），大鼠病毒（RV），基于上述病毒物种的载体 ，和/或能够积极产生上述病毒物种的细胞。 该药物组合物有利于胰腺癌的治疗。